Ainsua-Enrich Erola, Pedreño-Lopez Núria, Bracke Carmen, Ávila-Nieto Carlos, Rodríguez de la Concepción María Luisa, Pradenas Edwards, Trinité Benjamin, Marfil Silvia, Miranda Cristina, González Sandra, Toledo Ruth, Font Marta, Benet Susana, Escribà Tuixent, Jimenez-Moyano Esther, Peña Ruth, Cedeño Samandhy, Prado Julia G, Mothe Beatriz, Brander Christian, Izquierdo-Useros Nuria, Vergara-Alert Julia, Segalés Joaquim, Massanella Marta, Benitez Rosa María, Romero Alba, Molina-Morant Daniel, Blanco Julià, Clotet Bonaventura, Mateu Lourdes, Pedro-Botet María Luisa, Carrillo Jorge
IrsiCaixa AIDS Research Institute, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.
Infectious Diseases Department, Germans Trias i Pujol Hospital, Carretera Canyet s/n, Badalona, Catalonia 08916, Spain.
iScience. 2022 Nov 18;25(11):105455. doi: 10.1016/j.isci.2022.105455. Epub 2022 Oct 28.
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
大规模疫苗接种运动降低了新冠病毒疾病（COVID-19）的发病率和严重程度。在此，我们评估了主要存在抗体缺陷（PAD）的未感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者在接种三剂mRNA-1273疫苗后产生的免疫反应。PAD患者根据其免疫缺陷情况进行分类：未分类的原发性抗体缺陷（unPAD，n = 9）、常见变异型免疫缺陷（CVID，n = 12）、联合免疫缺陷（CID，n = 1）和伴免疫缺陷的胸腺瘤（TID，n = 1）。两剂疫苗接种后，unPAD患者和健康对照者（HCs，n = 10）产生了相似的疫苗诱导体液反应。然而，与HCs相比，CVID患者的结合和中和滴度降低。有趣的是，这些PAD组中产生刺突蛋白特异性γ干扰素（IFN-γ）的细胞水平较低。CVID个体的CD8T细胞也有所减少。CID和TID患者产生了细胞免疫反应，但未产生体液免疫反应。尽管第三剂疫苗增强了大多数PAD患者的体液免疫反应，但对扩大细胞免疫的作用有限。PAD个体中疫苗诱导的免疫反应是异质性的，应进行免疫监测以确定个性化的治疗策略。
